Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Chikungunya infections began to increase by the end of September 2022 in Paraguay, which declared on Feb. 24 that it was on alert due to the “atypical clinical and epidemiological behavior” of ...

Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said.Dr. Perera highlighted that the disease is spread by ...

Chikungunya infected children are being reported these days, said Dr. Deepal Perera, a specialist at the Lady Ridgeway ...

Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second phase 3 trial, in hot ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

Valneva has shared positive results from a late-stage study of its single-dose chikungunya vaccine in adolescents aged 12 to ...

Some of these agents, like the parasite that causes malaria, have produced illness in humans for thousands of years, while others such as the chikungunya and Zika viruses have emerged only very ...